Switzerland-based Silony Medical International has completed the acquisition of the global fusion business of US-based Centinel Spine with the aim of entering the US spinal fusion market.
Following the acquisition, the company changed its name to ‘Silony Spine’ to emphasise its focus on spine fusion technology. The company plans to utilise Centinel’s distribution network to propel the former’s growth in the US market.
Spinal fusion is a surgical procedure that involves joining two or more bones in the spine to form a single solid bone. This connection prevents bone movement, thereby, relieving pain.
A GlobalData market model forecasts the spinal fusion market to grow from $7.5bn in 2022 to $8.89bn by 2030. Most of the growth is expected for interbody devices which are expected to grow at a CAGR of 6.03%, from $2.7bn in 2022 to $4.1bn in 2030.
In addition to Centinel’s assets, Silony will also incorporate the US company’s personnel and update the latter’s interbody fusion platform, STALIF. The interbody fusion devices help to restore spinal balance and recreate spinal alignment and stability through surgery.
Other devices in the company’s portfolio include Verticale posterior screw and rod fusion platform, along with Roccia and Favo interbody fusion (IBF) systems.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
Your download email will arrive shortly
We are confident about the
quality of our Company Profiles. However, we want you to make the most
decision for your business, so we offer a free sample that you can download by
submitting the below form
Following the divestment of its fusion business, Centinel plans to focus on its total disc replacement technology platform, prodisc. The company’s prodisc catalogue generated $45m in revenue in 2022, as per Centinel’s financials.
Recent advancements in spinal fusion technology include Xenix Medical’s nanotechnology-based interbody fusion implants, receiving 510(k) clearance by the US Food and Drug Administration.